|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The ErbB2 receptor tyrosine kinase is overexpressed in approximately 15-20% of breast tumors and associated with aggressive disease and poor clinical outcome. p130Cas represents a nodal scaffold protein regulating cell survival, migration and proliferation in normal and pathological contexts. p130Cas overexpression in ErbB2 human breast cancer correlates with poor prognosis and metastasis formation.
|
30816273 |
2019 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrate a high-grade molecular homology between canine and human CAS, and show that enrichment of upregulated canine CAS genes strongly correlates with the enrichment of an independently derived human stromal signature in the TCGA breast tumour dataset.
|
31308057 |
2019 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Elevated p130Cas (Crk-associated substrate) levels are found in aggressive breast tumors and are associated with poor prognosis and resistance to standard therapeutics in patients. p130Cas signals majorly through its phosphorylated substrate domain (SD) that contains 15 tyrosine motifs (YxxP) which recruit effector molecules.
|
26867768 |
2016 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Elevated levels of p130(Cas) (Crk-associated substrate)/BCAR1 (breast cancer antiestrogen resistance 1 gene) are associated with aggressiveness of breast tumors.
|
25805500 |
2015 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, in silico microarray data analysis indicates that p130Cas and Cyclooxygenase-2 concomitant overexpression predicts poor survival and high probability of breast tumor recurrence.
|
23098208 |
2012 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Elevated levels of p130(Cas)/BCAR1 (Crk-associated substrate/breast cancer antiestrogen resistance 1) are found in aggressive breast tumors and are associated with tamoxifen resistance of mammary cancers. p130(Cas) promotes the integration of protein complexes involved in multiple signaling pathways frequently deregulated in breast cancer.
|
22431919 |
2012 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The ErbB2 oncogene is often overexpressed in breast tumors and associated with poor clinical outcome. p130Cas represents a nodal scaffold protein regulating cell survival, migration, and proliferation in normal and pathological cells.
|
20505116 |
2010 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Elevated expression of p130(Cas)/BCAR1 (breast cancer anti estrogen resistance 1) in human breast tumors is a marker of poor prognosis and poor overall survival.
|
19330798 |
2009 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells.
|
19029090 |
2009 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling.
|
17616674 |
2007 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A specific ELISA was developed to measure BCAR1 protein levels in 2593 primary breast tumor cytosols.
|
15448007 |
2004 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
A specific ELISA was developed to measure BCAR1 protein levels in 2593 primary breast tumor cytosols.
|
15448007 |
2004 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, high levels of BCAR1/pl30Cas protein in ER-positive primary breast tumours are associated with intrinsic resistance to tamoxifen treatment.
|
11693462 |
2001 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High BCAR1/p130Cas expression in primary breast tumour cytosol predicts a poor chance of response recurrent disease to tamoxifen treatment in patients with oestrogen receptor (ER)-positive breast carcinomas.
|
11008210 |
2000 |